BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors

(1)
LUND, Sweden and STRASBOURG, France, Dec. 21, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced they have received regulatory approval in Belgium for a clinical trial application (CTA) for a Phase l/lla study of the novel oncolytic vaccinia virus BT-001.
BT-001 is a best-in-class oncolytic
Vaccinia virus. It has been generated using Transgene's Invir.IO platform and its patented large-capacity VVcopTK-RR-

Related Keywords

Sweden ,United States ,France ,Belgium ,French ,Lucie Larguier ,Philippe Archinard ,Martin Welschof ,Mary Ann Chang ,Sylvie Berrebi ,Citigate Dewe Rogerson ,Astrazeneca ,Twitter ,Corporate Communications ,Bioinvent International ,Prnewswire Bioinvent International Ab ,Euronext Paris ,Artificial Intelligence ,Ann Chang ,Risk Factors ,Universal Registration Document ,ஸ்வீடந் ,ஒன்றுபட்டது மாநிலங்களில் ,பிரான்ஸ் ,பெல்ஜியம் ,பிரஞ்சு ,மேரி ஆண்டு சாங் ,ட்விட்டர் ,பெருநிறுவன தகவல்தொடர்புகள் ,செயற்கை உளவுத்துறை ,ஆண்டு சாங் ,ஆபத்து காரணிகள் ,உலகளாவிய பதிவு ஆவணம் ,